Avadel Pharmaceuticals plc (NASDAQ: AVDL) is -8.22% lower on its value in year-to-date trading and has touched a low of $9.50 and a high of $19.09 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AVDL stock was last observed hovering at around $12.44 in the last trading session, with the day’s gains setting it 0.52%.
Currently trading at $12.96, the stock is -0.98% and -10.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.74 million and changing 4.18% at the moment leaves the stock -15.58% off its SMA200. AVDL registered 18.25% gain for a year compared to 6-month loss of -18.80%. The firm has a 50-day simple moving average (SMA 50) of $14.5484 and a 200-day simple moving average (SMA200) of $15.3516.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -5.05% gain in the last 1 month and extending the period to 3 months gives it a -21.93%, and is 1.17% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.10% over the week and 3.80% over the month.
Avadel Pharmaceuticals plc (AVDL) has around 154 employees, a market worth around $1.25B and $95.15M in sales. Fwd P/E is 21.20. Profit margin for the company is -111.64%. Distance from 52-week low is 36.42% and -32.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-99.19%).
The EPS is expected to grow by 74.19% this year
208.0 institutions hold shares in Avadel Pharmaceuticals plc (AVDL), with institutional investors hold 83.46% of the company’s shares. The shares outstanding are 96.27M, and float is at 90.35M with Short Float at 12.14%. Institutions hold 79.47% of the Float.
The top institutional shareholder in the company is VIVO CAPITAL, LLC with over 3.97 million shares valued at $55.85 million. The investor’s holdings represent 4.332 of the AVDL Shares outstanding. As of 2024-06-30, the second largest holder is TRI LOCUM PARTNERS LP with 1.19 million shares valued at $16.72 million to account for 1.2973 of the shares outstanding. The other top investors are BIOIMPACT CAPITAL LLC which holds 0.78 million shares representing 0.8542 and valued at over $11.01 million, while KNOLL CAPITAL MANAGEMENT, LLC holds 0.6544 of the shares totaling 0.6 million with a market value of $8.44 million.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
The most recent transaction is an insider purchase by MCHUGH THOMAS S, the company’s Chief Financial Officer. SEC filings show that MCHUGH THOMAS S bought 2,000 shares of the company’s common stock on Jan 16 ’24 at a price of $14.50 per share for a total of $29000.0. Following the purchase, the insider now owns 80500.0 shares.
Avadel Pharmaceuticals plc disclosed in a document filed with the SEC on Dec 28 ’23 that McCamish Mark Anthony (Director) sold a total of 75,000 shares of the company’s common stock. The trade occurred on Dec 28 ’23 and was made at $14.53 per share for $1.09 million. Following the transaction, the insider now directly holds 67025.0 shares of the AVDL stock.
